

Cambridge University Press & Assessment
 978-1-108-96568-2 — Management of Complex Treatment-resistant Psychotic Disorders
 Michael Cummings, Stephen Stahl
 Copyright information
[More Information](#)



Shaftesbury Road, Cambridge CB2 8EA, United Kingdom
 One Liberty Plaza, 20th Floor, New York, NY 10006, USA
 477 Williamstown Road, Port Melbourne, VIC 3207, Australia
 314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India
 103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of Cambridge University Press & Assessment, a department of the University of Cambridge.

We share the University's mission to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org
 Information on this title: www.cambridge.org/9781108965682
 DOI: 10.1017/9781108963923

© Cambridge University Press & Assessment 2021

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press & Assessment.

First published 2021

A catalogue record for this publication is available from the British Library

Library of Congress Cataloging-in-Publication data

Names: Cummings, Michael A. (Michael Allen), 1951– editor. | Stahl, Stephen M., 1951– editor.
 Title: Management of complex treatment-resistant psychotic disorders / edited by Dr. Michael A. Cummings, Dr. Stephen M. Stahl. Description: Cambridge, United Kingdom ; New York : Cambridge University Press, 2021. | Includes bibliographical references and index. Identifiers: LCCN 2020055181 (print) | LCCN 2020055182 (ebook) | ISBN 9781108965682 (paperback) | ISBN 9781108963923 (ebook) Subjects: MESH: Psychotic Disorders – drug therapy | Psychotic Disorders – complications | Antipsychotic Agents – therapeutic use | Antipsychotic Agents – pharmacology | Psychopharmacology – methods | Drug Resistance Classification: LCC RM333.5 (print) | LCC RM333.5 (ebook) | NLM WM 200 | DDC 615.7/882–dc23
 LC record available at <https://lccn.loc.gov/2020055181>
 LC ebook record available at <https://lccn.loc.gov/2020055182>

ISBN 978-1-108-96568-2 Paperback

Cambridge University Press & Assessment has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Disclaimer: The opinions and viewpoints expressed herein are those of the editors and contributors and should not be construed to represent any official policy or position of the State of California, the California Department of State Hospitals, or any of the academic institutions associated with the editors or contributors.

Disclosures: Dr. Arguello, Dr. Arias, Dr. Cummings, Dr. O'Day, Dr. Schwartz, Dr. Striebel, and Dr. Warburton declare that they have nothing to disclose. Dr. Meyer reports having received speaking or advising fees from Alkermes, Forum, Merck, Otsuka-USA and Sunovion. Dr. Stahl reports having received advising fees, consulting fees, speaking fees and/or research grants from Acadia, Alkermes, Biomarin, Clintara, Eli-Lilly, EnVivo, Forest, Forum, GenoMind, JayMac, Lundbeck, Merck, Novartis, Orexigen, Otsuka-USA, PamLabs, Pfizer, RCT Logic, Servier, Shire, Sprout, Sunovion, Sunovion-UK, Taisho, Takeda, Teva, Tonix and Trius.